Alvocidib
- Generic Name
- Alvocidib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20ClNO5
- CAS Number
- 146426-40-6
- Unique Ingredient Identifier
- 45AD6X575G
- Background
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
- Indication
Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-08-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 48
- Registration Number
- NCT00003690
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020189
- Locations
- ๐บ๐ธ
Center for Cancer Research, Bethesda, Maryland, United States
๐บ๐ธWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00023894
- Locations
- ๐บ๐ธ
Simmons Cancer Center - Dallas, Dallas, Texas, United States
๐บ๐ธUniversity of Texas Medical Branch, Galveston, Texas, United States
๐บ๐ธRush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT00046917
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 33
- Registration Number
- NCT00005074
- Locations
- ๐จ๐ฆ
Toronto General Hospital, Toronto, Ontario, Canada
๐จ๐ฆNova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
๐จ๐ฆCancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006485
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.